"Four Biotech Stocks Poised for Breakout as Momentum Scores Rise"
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 08 2025
0mins
Should l Buy RNXT?
Source: Benzinga
Biotech Stocks Momentum Surge: Several biotech stocks have shown significant increases in their Momentum scores over the past week, indicating strong price movements and volatility, as assessed by Benzinga’s Edge Stock Rankings.
Top Performers: Key stocks include Tenaya Therapeutics, InflaRx NV, RenovoRx, and Alector Inc., each experiencing notable score increases due to factors such as strong quarterly performances, potential FDA policy shifts, and positive analyst upgrades.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNXT
Wall Street analysts forecast RNXT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.130
Low
3.00
Averages
5.63
High
12.50
Current: 1.130
Low
3.00
Averages
5.63
High
12.50
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RENOVORX REPORTS FY NET LOSS OF USD 11.168 MILLION
- Company Overview: Renovorx FY reported a net income of USD 11.168 million.
- Financial Performance: The financial results indicate a positive performance for the fiscal year.
- Market Impact: The reported income may influence investor confidence and market perception of Renovorx.
- Future Outlook: Analysts may look for further developments and projections based on this financial performance.
See More
RenovoRx Reports FY 2025 Financial Results with Private Placement
- Financial Performance: RenovoRx reported a FY 2025 GAAP EPS of -$0.32, aligning with expectations, yet revenue of $1.12 million fell short by $0.18 million, indicating challenges in revenue growth.
- Cash Position: As of December 31, 2025, RenovoRx had approximately $7.0 million in cash and cash equivalents, reflecting liquidity pressures in maintaining operational stability.
- Financing Activity: Following the fiscal year-end, RenovoRx closed a private placement on March 20, 2026, raising gross proceeds of $10 million and net proceeds of $9.2 million, which will help strengthen the company's balance sheet.
- Market Reaction: Despite the financing improving financial conditions, the failure to meet revenue expectations may negatively impact investor confidence, leading to potential stock price volatility.
See More
RENOVORX REPORTS FY OPERATING EXPENSES OF USD 13.306 MILLION
- Financial Overview: RenovorX reported operating expenses amounting to USD 13.306 million.
- Expense Breakdown: The financial details indicate a significant investment in operational activities.
See More
Multiple Companies Set to Report Earnings
- Progress Software Earnings Outlook: Progress Software Corporation (PRGS) is expected to report earnings per share of $1.18, reflecting a 10.28% increase year-over-year, indicating the company's consistent ability to exceed market expectations, which may further boost investor confidence.
- Phreesia Earnings Surge: Phreesia, Inc. (PHR) forecasts earnings per share of $0.09, representing a staggering 181.82% increase compared to the same quarter last year, highlighting the company's strong performance in the medical information systems sector, potentially attracting more investor interest.
- Virgin Galactic Earnings Forecast: Virgin Galactic Holdings, Inc. (SPCE) anticipates earnings per share of -$1.12, although still negative, this marks a 55.73% improvement year-over-year, suggesting recovery potential in the aerospace sector, which may influence market perceptions of its future growth.
- HireQuest Earnings Decline: HireQuest, Inc. (HQI) expects earnings per share of $0.12, down 36.84% from the same quarter last year, reflecting challenges faced in the staffing industry, which could negatively impact its stock price.
See More
RenovoRx TIGeR-PaC Trial Enrollment on Track for 2026 Completion
- Trial Milestone Achieved: RenovoRx has surpassed 100 randomized patients in its TIGeR-PaC clinical trial, remaining on track for enrollment completion in the first half of 2026, with final data expected in 2027, demonstrating the company's ongoing commitment and innovation in cancer treatment.
- Device Application Expansion: Select TIGeR-PaC cancer centers have begun using RenovoCath® as a stand-alone device for drug delivery in oncology management, which not only enhances treatment precision but may also improve patient outcomes and experiences.
- Clinical Trial Design: The TIGeR-PaC trial protocol requires 114 randomized patients and 86 events for final analysis; currently, 104 patients have been randomized with 72 events recorded, ensuring the statistical validity and scientific rigor of the trial.
- Market Potential: RenovoRx's IAG product candidate is under FDA evaluation, and if approved, it will provide new treatment options for pancreatic and bile duct cancer patients, representing significant market potential and societal value.
See More
RenovoRx Secures $10 Million in Oversubscribed Private Placement
- Financing Size: RenovoRx executed definitive securities purchase agreements with institutional investors, successfully raising approximately $10 million in an oversubscribed private placement, reflecting strong market confidence in its business prospects.
- Management Participation: Members of RenovoRx's executive management team and Board of Directors also participated in the private placement, further enhancing investor trust and support for the company's future development.
- Commercialization Acceleration: The financing is expected to enable RenovoRx to accelerate the commercialization of RenovoCath in 2026, aiming to increase revenue, reduce cash burn, and move towards achieving cash-flow breakeven operations.
- Clinical Trial Advancement: The proceeds will support RenovoRx's lead clinical program, the pivotal Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, with full enrollment expected by mid-2026 and results anticipated in 2027.
See More
RENOVORX REPORTS FY NET LOSS OF USD 11.168 MILLION
- Company Overview: Renovorx FY reported a net income of USD 11.168 million.
- Financial Performance: The financial results indicate a positive performance for the fiscal year.
- Market Impact: The reported income may influence investor confidence and market perception of Renovorx.
- Future Outlook: Analysts may look for further developments and projections based on this financial performance.
See More
RenovoRx Reports FY 2025 Financial Results with Private Placement
- Financial Performance: RenovoRx reported a FY 2025 GAAP EPS of -$0.32, aligning with expectations, yet revenue of $1.12 million fell short by $0.18 million, indicating challenges in revenue growth.
- Cash Position: As of December 31, 2025, RenovoRx had approximately $7.0 million in cash and cash equivalents, reflecting liquidity pressures in maintaining operational stability.
- Financing Activity: Following the fiscal year-end, RenovoRx closed a private placement on March 20, 2026, raising gross proceeds of $10 million and net proceeds of $9.2 million, which will help strengthen the company's balance sheet.
- Market Reaction: Despite the financing improving financial conditions, the failure to meet revenue expectations may negatively impact investor confidence, leading to potential stock price volatility.
See More
RENOVORX REPORTS FY OPERATING EXPENSES OF USD 13.306 MILLION
- Financial Overview: RenovorX reported operating expenses amounting to USD 13.306 million.
- Expense Breakdown: The financial details indicate a significant investment in operational activities.
See More
Multiple Companies Set to Report Earnings
- Progress Software Earnings Outlook: Progress Software Corporation (PRGS) is expected to report earnings per share of $1.18, reflecting a 10.28% increase year-over-year, indicating the company's consistent ability to exceed market expectations, which may further boost investor confidence.
- Phreesia Earnings Surge: Phreesia, Inc. (PHR) forecasts earnings per share of $0.09, representing a staggering 181.82% increase compared to the same quarter last year, highlighting the company's strong performance in the medical information systems sector, potentially attracting more investor interest.
- Virgin Galactic Earnings Forecast: Virgin Galactic Holdings, Inc. (SPCE) anticipates earnings per share of -$1.12, although still negative, this marks a 55.73% improvement year-over-year, suggesting recovery potential in the aerospace sector, which may influence market perceptions of its future growth.
- HireQuest Earnings Decline: HireQuest, Inc. (HQI) expects earnings per share of $0.12, down 36.84% from the same quarter last year, reflecting challenges faced in the staffing industry, which could negatively impact its stock price.
See More
RenovoRx TIGeR-PaC Trial Enrollment on Track for 2026 Completion
- Trial Milestone Achieved: RenovoRx has surpassed 100 randomized patients in its TIGeR-PaC clinical trial, remaining on track for enrollment completion in the first half of 2026, with final data expected in 2027, demonstrating the company's ongoing commitment and innovation in cancer treatment.
- Device Application Expansion: Select TIGeR-PaC cancer centers have begun using RenovoCath® as a stand-alone device for drug delivery in oncology management, which not only enhances treatment precision but may also improve patient outcomes and experiences.
- Clinical Trial Design: The TIGeR-PaC trial protocol requires 114 randomized patients and 86 events for final analysis; currently, 104 patients have been randomized with 72 events recorded, ensuring the statistical validity and scientific rigor of the trial.
- Market Potential: RenovoRx's IAG product candidate is under FDA evaluation, and if approved, it will provide new treatment options for pancreatic and bile duct cancer patients, representing significant market potential and societal value.
See More
RenovoRx Secures $10 Million in Oversubscribed Private Placement
- Financing Size: RenovoRx executed definitive securities purchase agreements with institutional investors, successfully raising approximately $10 million in an oversubscribed private placement, reflecting strong market confidence in its business prospects.
- Management Participation: Members of RenovoRx's executive management team and Board of Directors also participated in the private placement, further enhancing investor trust and support for the company's future development.
- Commercialization Acceleration: The financing is expected to enable RenovoRx to accelerate the commercialization of RenovoCath in 2026, aiming to increase revenue, reduce cash burn, and move towards achieving cash-flow breakeven operations.
- Clinical Trial Advancement: The proceeds will support RenovoRx's lead clinical program, the pivotal Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, with full enrollment expected by mid-2026 and results anticipated in 2027.
See More
